Stay updated on GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial
Sign up to get notified when there's something new on the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page.

Latest updates to the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision v3.4.2 was added to the history; the prior funding notice and v3.4.1 entry were removed.SummaryDifference0.8%

- Check21 days agoChange DetectedAdded a site-wide notice regarding government funding delays and updated the revision from v3.4.0 to v3.4.1.SummaryDifference0.8%

- Check28 days agoChange DetectedAdded a 'Show glossary' option, color-coded highlights for additions (green) and deletions (red) in the study history, and a revision note showing v3.4.0 replacing v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check35 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no changes to study data or page content, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedThe record now shows Active, not recruiting and an updated title reflecting Relapse/Refractory AML. It also adds new sections including IPDSharing, Contacts/Locations, Study Design, Conditions, Study Description, Oversight, Sponsor/Collaborators, and Recruitment Status.SummaryDifference2%

- Check64 days agoChange DetectedAdded a new revision entry (Revision: v3.3.3) to the study's Record History. Removed the HHS Vulnerability Disclosure item and Revision: v3.3.2.SummaryDifference0.2%

Stay in the know with updates to GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page.